Written by: Andrew Kowalski, PharmD and Osama Abdelghany, PharmD, MHA, BCOP -Smilow Cancer Hospital at Yale New Haven HealthDownload Here Description: There are a number of treatment options for patients with follicular lymphoma that has relapsed or is refractory to first line options. The purpose of this PQI is to discuss appropriate patient identification and […]

Written by: Katie Carter, PharmD, BCPS, IU Simon Cancer Center Download Here Description: The purpose of this PQI is to highlight tucatinib and its usage and management in advanced unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens in the metastatic setting. Background: Tucatinib is an oral tyrosine kinase […]

Written By: Andrew Kuykendall, MD; Katherine Tobon, PharmD, BCOP; Syeda Saba Kareem PharmD, BCOP Moffitt Cancer Center DOWNLOAD HERE Description: This PQI will discuss the initiation and management of patients receiving avapritinib for Advanced Systemic Mastocytosis Background: Avapritinib is a potent tyrosine kinase inhibitor that targets platelet-derived growth factor receptor alpha (PDGFRA) and KIT exon […]

Written by: Yonatan Resnick, PharmD, New England Cancer Specialists Download Here  Description: This PQI will discuss the development and rationale of the oral DNMT/CDA inhibitor for the management of intermediate-1, intermediate-2, and high-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Background: Decitabine/cedazuridine is a fixed-dose combination of the hypomethylating agent decitabine and the cytidine […]

Written by: Lauren Trisler, PharmD, BCOP – Carle Cancer Center Download Here Description: Daratumumab injection is an anti-CD38 monoclonal antibody (mAb) FDA approved for use in a range of multiple myeloma patients including first line, transplant ineligible and relapse/refractory.1 The subcutaneous formulation (DARZALEX FASPRO®) is not indicated for front-line transplant eligible patients but is indicated for […]

Written by: Joshua Nubla, PharmD, NCODA Download Here  Description: This PQI is developed to provide guidance to genomic testing with respect to larotrectinib.   Background: Larotrectinib is indicated for the treatment of adult and pediatric patients with solid tumors that: Have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation […]

Written by: Trey McNiel, PharmD, Georgia Cancer Specialists Download Here Description: The purpose of this PQI is to discuss the clinical considerations around the use of acalabrutinib (Calquence®) to optimize the outcomes for patients with CLL/SLL. Background: Acalabrutinib is a Bruton tyrosine kinase (BTK) inhibitor initially indicated for mantle cell lymphoma (MCL) patients who have […]

Written by: Alyson Leonard, PharmD, BCPS, BCOP, Cone Health Download Here Description: Osimertinib is an indicated and preferred first line treatment option for patients with Epidermal Growth Factor Receptor (EGFR) gene mutation positive Non-Small Cell Lung Cancer (NSCLC) with Exon 19 deletion or exon 21 L858R and with EGFR T790M mutation positive disease with progression on/after EGFR tyrosine kinase inhibitor- based […]

Written by: Joshua Nubla, PharmD, NCODA Download Here Description: The purpose of this PQI is to discuss Stage III Non-small cell lung cancer (NSCLC) and patient eligibility. Background: Within the category of Lung Cancer, approximately 80% to 85% of lung cancers are NSCLC.3,5 Treatment for stage III NSCLC may include combinations of radiation, chemotherapy, and/or […]

Written By: Todd Murphree, PharmD Clearview Cancer Institute Download Here Description of PQI: Ruxolitinib is a selective Jak2 inhibitor used for the treatment of myelofibrosis (MF). This PQI will review the close monitoring of platelets required to ensure appropriate dose and avoid severe thrombocytopenia due to the therapy. Background: Ruxolitinib is FDA approved for the treatment […]

Written by: Lauren Held, PharmD, BCOP – Seattle Cancer Care Alliance Download Here Copanlisib is an intravenous (IV) phosphatidylinositol 3-kinase (PI3K) inhibitor indicated for the treatment of relapsed follicular lymphoma (FL) in patients that have received at least two prior systemic therapies.1 This PQI will review how to manage select toxicities associated with copanlisib.

Written By: Chris Sellers, RPh, Texas Oncology Download Here Description: The purpose of this PQI is to provide information on the management of common adverse events, follow-up with patients, and dose modifications. Dose adjustments are common and greatly reduced frequency and severity of adverse reactions. In Lux-Lung 3, 43% maintained the 40 mg starting dose, […]